🇺🇸 FDA
Patent

US 11040091

Cycle adenosine monophosphate-incompetent adenylyl cyclase and compositions and methods for treating heart failure and increasing cardiac function

granted A61KA61K38/51A61P

Quick answer

US patent 11040091 (Cycle adenosine monophosphate-incompetent adenylyl cyclase and compositions and methods for treating heart failure and increasing cardiac function) held by The Regents of the University of California expires Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Jun 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K38/51, A61P, A61P43/00, A61P9/00